Background:Patients with early stage breast cancer with same treatment strategy can have markedly different outcomes. Human epidermal growth factor receptor 2 (HER2/nue) gene amplification or the subsequent overexpression of protein has been proved to be associated with patient's outcome and response to anthracyclins-based regimens.Objectives:This study assessed prognostic value of HER2/nue marker in patients with early stage breast cancer who received adjuvant chemotherapy with anthracyclins-based regimens.Materials and Methods:Fifty tissue samples from patients with primary breast cancer of moderate risk receiving sequential adjuvant chemotherapy with anthracyclins-based regimens were assessed to evaluate HER2/nue gene status (quantified by Immunohistochemistry and fluorescence in situ hybridization) retrospectively. Besides, correlation of HER2/neu with patients' characteristics and outcome was studied.Results:HER2/neu amplification was identified in 19 (38%) of 50 patients. No significant difference regarding HER2/neu status was seen in clinic pathological characteristics of patients. Although Progression Free Survival (PFS) was shorter in HER2 overexpressed group, but uni/multivariate analysis adjusted for HER2 overexpression, nodal involvement, hormone receptor status, age and tumor size revealed no significant predictive and/or prognostic value for HER2 regarding PFS.Conclusions:This study on a limited number of patients treated with adjutant anthracyclins-based regimens, revealed that HER2/neu is not a unique strong predictor for outcome, thus according to combination of HER2/neu status and other clinical factors, it is necessary to distinguish patients at high risk of recurrence.
Background Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung cancers. This post-marketing surveillance (PMS) study aimed to evaluate the safety of Pemetrexed (Alvopem®, NanoAlvand, Iran) in Iranian patients with lung cancer or mesothelioma. Methods The present study is an observational, single-center, open-label, and post-authorization study. All eligible non-squamous NSCLC and malignant pleural mesothelioma (MPM) patients who received pemetrexed based on the physicians’ decision, were enrolled. Results A total of 199 patients with non-squamous NSCLC [186 patients (93.47%) or MPM (12 patients (6.03%)] were enrolled from March 2016 to February 2020. The most common reported adverse event (AE) was anemia (89.39%), followed by neutropenia (28.79%) and leukopenia (24.75%). The most important grade 3 AEs were anemia and neutropenia, with the incidence rate of 3.54% and 7.58%, respectively. No grade 4 AEs were reported. Moreover, the results of our study showed negative statistically significant correlations between patients’ age and mean neutrophil count (r = − 0.17; P = 0.0156) and hemoglobin (r = − 0.16; P = 0.0201) in all six visits. Conclusions The results of this open-label, observational PMS showed that Pemetrexed (Alvopem®) is safe in patients with non-squamous NSCLC patients receiving pemetrexed-containing regimens. Trial registration: The trial was registered at ClinicalTrials.gov (NCT04843007) in April 13th, 2021.
e13596 Background: Several studies showed disparities in terms of gender in lung cancer pattern. As we know, there is limited available data from lung cancer trends by gender in Iran and information reported in previous Iranian studies has become outdated. Methods: This observational study included data of Lung Cancer which were obtained from National Institute of Tuberculosis and Lung Disease (NRITLD), Masih Daneshvari Hospital,from January 1, 1996 to June 1, 2018. Overall survival (OS) and progression free survival (PFS) were estimated for each gender at several time points by the Kaplan-Meier method. Results: Characteristics of 1599 patients are shown in Table. Adenocarcinoma was most prevalent pathology in both sex and incidence of this histology increased in men during all study periods except 2002-2006. Notably, Adenocarcinoma has an increasing pattern especially after 2006 in women. Most prevalent Stage was advanced stages in both sex. Mean OS were 9.84±0.56 and 10.27±0.91 months in male and female respectively (P = 0.769). Also, mean PFS was non-significantly longer in men than women (7.6±0.49 vs 7.4±0.39, P = 0.903).Cox regression multivariate analysis showed only significant effect for advanced/extensive stages on OS(P = 0.015). Conclusions: The findings highlight important characteristics of the lung cancer epidemic; women are diagnosed at younger age and were less smoker than men. It is necessary for all chealthcare systems to assess the cancer burden periodically and gender differences should be considered for screening guidelines, preventive strategies, and Treatment. [Table: see text]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.